For patients with sarcoidosis involving organs, those with cardiac lesions have especially poor prognosis. Among sarcoidosis patients, those in Japan have higher rates of cardiac involvement of sarcoidosis (CS) than do those in other countries. Therefore, the Japanese medical community has put great efforts into managing CS patients and has developed research activities. In this regard, the Japanese Ministry of Health & Welfare (JMHW) issued CS diagnostic guidelines in 1993 and these have been widely used around the world. The Japanese Circulation Society updated its nuclear medicine guidelines in 2010 and recommended using nuclear imaging to diagnose CS. 
A
mong issues for sarcoidosis patients in Japan is the relatively high incidence of cardiac involvement, similar to the case in Scandinavian countries (1) . Cardiacinvolvement sarcoidosis (CS) has an extremely poor prognosis, and careful management is required. In this regard, the Japanese medical community has put great effort into the care of CS patients and has done substantial research (2, 3). (PET) for detecting inflammatory myocardial regions in CS (7, 8 Table 2 ). In the histopathologically diagnosed group, the positivity rate for detection of cardiac sarcoidosis may be low owing to sampling errors in myocardial biopsy. Hence, in actual clinical settings, the number of cases in the clinically diagnosed group may be higher than in the histopathologically diagnosed group. Upon diagnosis of cardiac sarcoidosis, it is important to determine the disease activity in order to develop a treatment strategy, assess severity, predict prognosis, and tailor steroid therapy. Nuclear imaging is useful in detecting inflammation. 67 Gallium ( 67 Ga) imaging has been used for this purpose, but 67 Ga imaging has low diagnostic sensitivity owing to its low image resolution. Given this circumstance, 18 F-FDG PET has been used to diagnose cardiac sarcoidosis.
JCS guidelines for nuclear medicine in the diagnosis of cardiac sarcoidosis
The Japanese Circulation Society (JCS) has issued and (13, 14) . A high-fat meal may be used to shift myocardial metabolism from glucose metabolism to fatty acid metabolism (15) . Both approaches may be used to reduce physiological FDG uptake. However, by 2012 only one institution had reported the usefulness of a high-fat meal for fasting 18 F-FDG PET imaging. Therefore, the JSNC committee included only the low-carbohydrate diet in its recommendations for 18 F-FDG PET preparation.
Another possible approach to reducing physiological 18 F-FDG uptake is to use unfractionated heparin. Unfractionated heparin actually increases plasma free fatty acid (FFA) concentration (16) and is believed to shift myocardial metabolism from glucose to fatty acid. However, this possibility has not been proven. Since the first study involving a relatively large population in the detection of CS using 18 F-FDG PET used heparin (17), many facilities have used heparin in clinical practice. Heparin has some serious side effects and therefore there are some concerns with using it (18) .
Therefore, the JSNC committee did not include heparin administration as part of its preferred preparation. Further, the committee issued a precaution regarding heparin use and pointed out the importance of further evaluations in that regard.
F-FDG data acquisition
Although most of the FDG PET studies for detecting CS used 2D data acquisition, the current PET/CT scanners use 3D data acquisition. Data from 3D acquisition was limited at that time although there were some guidelines for 18 F-FDG PET/CT in oncology (19) . Based on the previously issued guidelines, the committee recommended an Image acquisition should begin 60 minutes after FDG administration, similar to the case for 18 F-FDG PET viability study (10, 20) . Given the importance of cardiac involvement in sarcoidosis, it would be preferable to have cardiac spot scans for up to 10 minutes. Both hands should be raised during data acquisition.
F-FDG image interpretation
When examining 18 F-FDG PET imaging, it is important to consider common sites of cardiac lesions in sarcoidosis. The most common site is the left ventricular free wall followed by the intraventricular septum (21) . In cases of conduction abnormality, it is quite important to look at the intraventricular septum (22) .
The diagnostic criteria for 18 F-FDG PET imaging are based on of the those defined within a previous study by Ishimaru et al. (17) . Negative uptake includes no FDG uptake in the myocardium, identified as "none", and diffuse homogenous 18 F-FDG uptake, identified as "diffuse".
Positive uptake includes a focal uptake pattern. Considering the granuloma formation of sarcoidosis, the focal pattern is consistent with pathophysiology. There were some discussions among committee members about including the "focal and diffuse" pattern showing false positive uptake. There were some concerns that this pattern may be associated with insufficient patient preparation. However, in patients with heart failure, myocardium sometimes shifts from metabolizing predominantly fatty acids to metabolizing predominantly glucose. In this regard, some CS patients with poor LV function may have diffuse 18 F-FDG uptake and thus this pattern should be positive.
Conclusions and future directions
This JSNC recommendation is the first to propose a standardized approach to PET imaging as one of the major diagnostic criteria. In addition, since the publication of this recommendation, a significant amount of data has been published. In light of these recent data, this JSNC recommendation should be updated.
